Beijing Honglin Pharmaceutical

Beijing Honglin Pharmaceutical Co., Ltd. is a commercial-stage pharmaceutical company specializing in the development, manufacturing, and commercialization of advanced sustained- and controlled-release formulations. Founded in 1993 and headquartered in Beijing, China, the company operates as a wholly foreign-owned enterprise under GoeGoe Honglin Pharmaceutical Co. Beijing Honglin Pharmaceutical leverages proprietary formulation technologies, including an iteration of ALZA's OROS technology, to develop high-quality generic drugs with optimized pharmacokinetic profiles. Its commercial portfolio spans seven therapeutic areas, including cardiovascular, endocrine, digestive, respiratory, and psychiatric systems. Key products such as Jiubaoping (nifedipine controlled-release tablets) and Letoufu (glipizide controlled-release tablets) are widely adopted in China's national volume-based procurement programs.